DENTALEX
ActiveSummary
DENTALEX has been active since 2008 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €40,689 and a net result of €28,765. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 40% of 60 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (low).
Checked score
Score 2025
Axes · tick = 2024
Profitability82▼-7
Solvency40▼-4
Growth78=
Track record100
Bankruptcy probability, 12 months
0.5%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €2,000 at 30 days acceptable
Liquidity short (current ratio 0.44 against 0.49 in 2024; short-term debt: 47.3% and cash: 1.5% of total assets), and 84.7% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Three signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies
more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 30-01-2026, 1 day ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
1 d early
2024
on the day
2023
19 d late
2022
on the day
2021
3 d early
2020
2 d early
2019
6 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 3 days after the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 30-06-2026 and is due by 31-01-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
30-06-2026 close28-09-2026 today31-01-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Public money How does this company compare with its sector?Sector benchmark
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, micro schema
Equity
€40,689▼ 19.2%
2024 · €50,368
Total assets
€266,453▼ 1.1%
2024 · €269,353
Net result
€28,765▼ 35.1%
2024 · €44,300
Working capital
-€70,615▼ 21.5%
2024 · -€58,140
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Operating result€48,730▲ 54.7%-€45,023€20,483€58,496▲ 186%€41,498▼ 29.1%
Net result€32,476above the sector's middle half▲ 55.6%-€60,541below the sector's middle half€1,873within the sector's middle half€44,300within the sector's middle half▲ 2,265%€28,765within the sector's middle half▼ 35.1%
Equity€64,735within the sector's middle half▲ 101%€4,195within the sector's middle half▼ 93.5%€6,067within the sector's middle half▲ 44.6%€50,368within the sector's middle half▲ 730%€40,689within the sector's middle half▼ 19.2%
Total assets€253,231within the sector's middle half▼ 3.5%€342,334within the sector's middle half▲ 35.2%€320,314within the sector's middle half▼ 6.4%€269,353within the sector's middle half▼ 15.9%€266,453within the sector's middle half▼ 1.1%
Debt€188,496▼ 18.1%€338,140▲ 79.4%€314,247▼ 7.1%€218,986▼ 30.3%€225,764▲ 3.1%
Working capital-€18,027▼ 46.5%-€99,799▼ 454%-€107,381▼ 7.6%-€58,140▲ 45.9%-€70,615▼ 21.5%
Solvency25.6%within the sector's middle half▲ 13.3pp1.2%within the sector's middle half▼ 24.3pp1.9%below the sector's middle half▲ 0.7pp18.7%within the sector's middle half▲ 16.8pp15.3%within the sector's middle half▼ 3.4pp
Staff (FTE)1.3▲ 62.5%2▲ 53.8%1▼ 50.0%2▲ 100%2=
above
within
below
the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 29% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €266,453
Fixed assets
€211,118 ▼ 0.6%
Current assets
€55,334 ▼ 2.9%
Equity and liabilities €266,453
Equity
€40,689 ▼ 19.2%
Debt
€225,764 ▲ 3.1%
Debt's share of the balance-sheet total rises from 81.3% to 84.7%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
€72,707▼
2024 · €100,965
Cash flow
€59,974▼
2024 · €86,769
Current ratio
0.44▼
2024 · 0.49
Quick ratio
0.20▼
2024 · 0.20
Debt to equity
5.55▲
2024 · 4.35
ROE
70.7%▼
2024 · 88.0%
ROA
10.8%▼
2024 · 16.4%
Interest coverage
9.68▲
2024 · 6.23
Debt ≤ 1 year
€125,949▲
2024 · €115,120
Debt > 1 year
€99,815▼
2024 · €103,865
Income taxes
€7,996▲
2024 · €285
Staff costs
€66,335▲
2024 · €61,441
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 5,053 companies that looked in July 2024 the way this one looks now, 1.5% went bankrupt within 24 months and 96% are still going.
- Micro
- 10 to 20 years old
- solvency 10 to 30%
- a profit of 5% of the balance sheet or more
1.5%
went bankrupt
2.3%
stopped otherwise
96%
still going
A further 0.4% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a bankruptcy probability of 0.5% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,662 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.4% |
| 3 | 0.5% | 0.5% |
| 4 | 0.6% | 0.7% |
| 5 | 0.8% | 0.9% |
| 6 | 1.2% | 1.3% |
| 7 | 1.5% | 1.7% |
| 8 | 1.7% | 1.7% |
| 9 | 2.7% | 2.8% |
| 10 | 5.3% | 5.7% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 75% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 5,053 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | €913 | €12,895 | €26,000 | - | - |
| Remuneration, social security and pensions62 | - | €61,224 | €38,653 | €61,441 | €66,335 | ▲ 8.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €50,166 | €44,577 | €46,397 | €42,468 | €31,210 | ▼ 26.5% |
| Other operating charges640/8 | - | €3,310 | €2,753 | €1,776 | €1,507 | ▼ 15.1% |
| Non-recurring operating charges66A | - | - | - | €2,525 | - | - |
| Gross operating margin9900 | €144,572 | €64,088 | €108,287 | €166,706 | €140,550 | ▼ 15.7% |
| Operating profit (loss)9901 | €48,730 | -€45,023 | €20,483 | €58,496 | €41,498 | ▼ 29.1% |
| Financial income75/76B | - | €648 | €154 | €2,297 | €2,771 | ▲ 20.6% |
| Recurring financial income75 | €1,705 | €648 | €154 | €2,297 | €2,771 | ▲ 20.6% |
| Financial charges65/66B | - | €12,921 | €18,019 | €16,208 | €7,508 | ▼ 53.7% |
| Recurring financial charges65 | €7,498 | €12,921 | €18,019 | €16,208 | €7,508 | ▼ 53.7% |
| Profit (loss) for the period before taxes9903 | €42,937 | -€57,296 | €2,618 | €44,585 | €36,761 | ▼ 17.5% |
| Income taxes67/77 | €10,461 | €3,245 | €745 | €285 | €7,996 | ▲ 2,706% |
| Profit (loss) for the period9904 | €32,476 | -€60,541 | €1,873 | €44,300 | €28,765 | ▼ 35.1% |
| Profit (loss) for the period to be appropriated9905 | €32,476 | -€60,541 | €1,873 | €44,300 | €28,765 | ▼ 35.1% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €253,231 | €342,334 | €320,314 | €269,353 | €266,453 | ▼ 1.1% |
| Fixed assets21/28 | €156,066 | €285,223 | €252,288 | €212,373 | €211,118 | ▼ 0.6% |
| Intangible fixed assets21 | €2,429 | €1,431 | €432 | - | - | - |
| Tangible fixed assets22/27 | €153,637 | €283,792 | €251,855 | €212,373 | €211,118 | ▼ 0.6% |
| Land and buildings22 | - | €188,946 | €176,598 | €162,548 | €148,498 | ▼ 8.6% |
| Plant, machinery and equipment23 | - | €65,744 | €52,268 | €29,496 | €37,636 | ▲ 27.6% |
| Furniture and vehicles24 | - | €12,388 | €9,201 | €7,294 | €8,799 | ▲ 20.6% |
| Other tangible fixed assets26 | - | €16,714 | €13,788 | €13,036 | €16,185 | ▲ 24.2% |
| Current assets29/58 | €97,165 | €57,111 | €68,026 | €56,980 | €55,334 | ▼ 2.9% |
| Stocks and contracts in progress3 | €35,138 | €30,989 | €27,334 | €33,849 | €30,343 | ▼ 10.4% |
| Stocks30/36 | - | €30,989 | €27,334 | €33,849 | €30,343 | ▼ 10.4% |
| Amounts receivable within one year40/41 | €47,904 | €8,368 | €17,152 | €20,166 | €18,808 | ▼ 6.7% |
| Trade receivables40 | - | €8,284 | €17,152 | €10,315 | €2,280 | ▼ 77.9% |
| Other amounts receivable41 | - | €84 | - | €9,852 | €16,528 | ▲ 67.8% |
| Cash at bank and in hand54/58 | €14,123 | €17,754 | €23,404 | €2,099 | €3,933 | ▲ 87.4% |
| Deferred charges and accrued income490/1 | - | - | €136 | €866 | €2,249 | ▲ 160% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €253,231 | €342,334 | €320,314 | €269,353 | €266,453 | ▼ 1.1% |
| Equity10/15 | €64,735 | €4,195 | €6,067 | €50,368 | €40,689 | ▼ 19.2% |
| Contributions10/11 | - | €6,200 | €6,200 | €6,200 | €6,200 | = |
| Reserves13 | €58,535 | €58,535 | €58,535 | €58,535 | €34,489 | ▼ 41.1% |
| Non-distributable reserves130/1 | - | €1,860 | €1,860 | €1,860 | €1,860 | = |
| Reserves not available under the articles1311 | - | €1,860 | €1,860 | €1,860 | €1,860 | = |
| Distributable reserves133 | - | €56,675 | €56,675 | €56,675 | €32,629 | ▼ 42.4% |
| Profit (loss) carried forward14 | -€35,130 | -€60,541 | -€58,668 | -€14,367 | - | - |
| Amounts payable17/49 | €188,496 | €338,140 | €314,247 | €218,986 | €225,764 | ▲ 3.1% |
| Amounts payable after more than one year17 | €73,303 | €181,229 | €138,839 | €103,865 | €99,815 | ▼ 3.9% |
| Financial debts170/4 | - | €181,229 | €138,839 | €103,865 | €99,815 | ▼ 3.9% |
| Amounts payable within one year42/48 | €115,192 | €156,910 | €175,408 | €115,120 | €125,949 | ▲ 9.4% |
| Current portion of amounts payable after more than one year42 | - | €56,587 | €48,637 | €34,974 | €24,683 | ▼ 29.4% |
| Financial debts43 | - | €28,199 | €47,394 | €22,000 | - | - |
| Credit institutions430/8 | - | €28,199 | €47,394 | €22,000 | - | - |
| Trade debts44 | €7,414 | €27,656 | €55,801 | €35,490 | €33,857 | ▼ 4.6% |
| Suppliers440/4 | - | €27,656 | €55,801 | €35,490 | €33,857 | ▼ 4.6% |
| Taxes, remuneration and social security45 | - | €28,599 | €13,180 | €22,657 | €31,161 | ▲ 37.5% |
| Taxes450/3 | - | €9,772 | €3,815 | €7,326 | €15,118 | ▲ 106% |
| Remuneration and social security454/9 | - | €18,827 | €9,365 | €15,331 | €16,043 | ▲ 4.6% |
| Other amounts payable47/48 | - | €15,869 | €10,396 | - | €36,248 | - |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €32,476 | -€60,541 | €1,873 | €44,300 | €28,765 | ▼ 35.1% |
| + Depreciation and write-downs630 | €50,166 | €44,577 | €46,397 | €42,468 | €31,210 | ▼ 26.5% |
| Operating cash flow (approximation) | €82,642 | -€15,963 | €48,270 | €86,769 | €59,974 | ▼ 30.9% |
| Investment in fixed assets (approximation) | - | -€173,734 | -€13,462 | -€2,554 | -€29,955 | ▼ 1,073% |
| Change in cash | - | €3,632 | €5,650 | -€21,306 | €1,834 | ▲ 109% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
30-01
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-01
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
30-06
Financial
Highest result since 2019net €44,300 ▲2,265%
Operating result €58,496, net result €44,300, both a record.
19-02
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 19 days late
2023
30-06
Financial
Back to profitnet €1,873
Net result €1,873 after one loss-making year.
31-01
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
30-06
Financial
Weakest financial yearnet -€60,541
Net result drops to -€60,541, the lowest in the series; recovery starts the following year.
28-01
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
29-01
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
06-02
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema · 6 days late
2019
15-02
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema · 15 days late
2017
18-12
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema
2016
06-12
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 3 acts read
About the unread acts
We know of 3 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
3 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Schilde · 1 establishment unit since 2008
Ground area
1,805 m²
Building footprint
338 m²
Volume, LiDAR
1,878 m³
2 parcels, Flanders · tallest building 11.8 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
DENTALEX
since 20082.168.985.425
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11041B0311/00Z005 | Flanders | 1,652 m² | 1 · 239 m² | 11.8 m · 2 fl. |
| 11041B0311/00F005 | Flanders | 153 m² | 1 · 99 m² | 9.0 m · 2 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Public money · subsidies and aid
Flemish government
2025 · 1 entry · 194 EUR awarded · 194 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 1 | 194 EUR | 194 EUR |
Similar companies · same sector, comparable size
MyCombiLab
BE 1017.366.682
Antwerpen · Eq €40,585
C&J Laboratories Belgium
BE 0645.680.597
Sint-Niklaas · Eq €37,338
Asterion Therapeutics
BE 0715.602.553
Beveren-Kruibeke-Zwijndrecht · Eq €34,965
NEIRYNCK en VOGT
BE 0464.104.616
Schelle · Eq €26,155
Highstar Engineering
BE 0685.983.703
Diepenbeek · Eq €66,345
Of 97 companies in sector 21209 we hold annual accounts for 74. 26 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded18-01-2008
Fiscal year end30-06
Activities, NACEBEL 2025
21209Manufacture of basic pharmaceutical products and pharmaceutical preparations
96220Beauty care and other beauty treatments
E-invoicing
Reachable via Peppol
Peppol ID
0208:0895296637
Also
9925:BE0895296637
Registered
20-11-2025
Register as of 27 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.